NASDAQ:VINC Vincerx Pharma (VINC) Stock Price, News & Analysis → This Apple-like Innovator is Revolutionizing Healthcare (From Wall Street Star) (Ad) Free VINC Stock Alerts $0.72 +0.03 (+3.87%) (As of 08:40 AM ET) Add Compare Share Share Today's Range$0.72▼$0.7250-Day Range$0.69▼$8.0652-Week Range$0.61▼$9.37Volume6,780 shsAverage Volume1.10 million shsMarket Capitalization$15.36 millionP/E RatioN/ADividend YieldN/APrice Target$5.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Vincerx Pharma alerts: Email Address Vincerx Pharma MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside624.0% Upside$5.00 Price TargetShort InterestHealthy5.98% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.10Based on 9 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.62) to ($0.48) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.57 out of 5 starsMedical Sector467th out of 914 stocksPharmaceutical Preparations Industry215th out of 427 stocks 3.5 Analyst's Opinion Consensus RatingVincerx Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageVincerx Pharma has only been the subject of 1 research reports in the past 90 days.Read more about Vincerx Pharma's stock forecast and price target. Previous Next 4.0 Short Interest Percentage of Shares Shorted5.98% of the float of Vincerx Pharma has been sold short.Short Interest Ratio / Days to CoverVincerx Pharma has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Vincerx Pharma has recently decreased by 14.17%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldVincerx Pharma does not currently pay a dividend.Dividend GrowthVincerx Pharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for VINC. Previous Next 1.1 News and Social Media Coverage News SentimentVincerx Pharma has a news sentiment score of -0.10. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.42 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Vincerx Pharma this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for VINC on MarketBeat in the last 30 days. This is a decrease of -98% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Vincerx Pharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -20% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Vincerx Pharma insiders have not sold or bought any company stock.Percentage Held by Insiders22.90% of the stock of Vincerx Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions44.02% of the stock of Vincerx Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Vincerx Pharma's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Vincerx Pharma are expected to grow in the coming year, from ($0.62) to ($0.48) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Vincerx Pharma is -0.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Vincerx Pharma is -0.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVincerx Pharma has a P/B Ratio of 1.33. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Vincerx Pharma's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Wall Street StarThis Apple-like Innovator is Revolutionizing HealthcareAI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.Click here to learn more about the booming eHealth industry About Vincerx Pharma Stock (NASDAQ:VINC)Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors. The company's preclinical stage product candidates include VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is based in Palo Alto, California.Read More VINC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VINC Stock News HeadlinesMay 17 at 6:52 AM | americanbankingnews.comLeerink Partnrs Equities Analysts Raise Earnings Estimates for Vincerx Pharma, Inc. (NASDAQ:VINC)May 15, 2024 | msn.comVincerx Pharma GAAP EPS of -$0.58May 15, 2024 | finanznachrichten.deVincerx Pharma, Inc.: Vincerx Pharma Reports First Quarter 2024 Financial Results and Provides Corporate UpdateMay 14, 2024 | investorplace.comVINC Stock Earnings: Vincerx Pharma Misses EPS for Q1 2024May 14, 2024 | globenewswire.comVincerx Pharma Reports First Quarter 2024 Financial Results and Provides Corporate UpdateApril 26, 2024 | msn.comWhy Vincerx Pharma (VINC) Stock Is FallingApril 26, 2024 | globenewswire.comVincerx Pharma Announces Pricing of Underwritten Public Offering of Common Stock and WarrantsApril 25, 2024 | globenewswire.comVincerx Pharma Announces Proposed Underwritten Public Offering of Common Stock and WarrantsApril 23, 2024 | nasdaq.comVincerx Pharma, Inc. Common Stock (VINC)April 12, 2024 | finance.yahoo.comAgendia’s BluePrint Included in German Oncology Group GuidelinesApril 10, 2024 | finance.yahoo.comThe Rise of Zyn: The Oral Nicotine Product Going ViralApril 10, 2024 | markets.businessinsider.comVincerx Pharma Inc (VINC) Gets a Buy from Leerink PartnersApril 9, 2024 | msn.comACOR, HUBC and DATS among pre-market losersApril 9, 2024 | msn.comVincerx in selloff after early-stage data for cancer therapyApril 9, 2024 | investorplace.comWhy Is Vincerx Pharma (VINC) Stock Down 64% Today?April 8, 2024 | globenewswire.comVincerx Pharma Presents Positive Preliminary Phase 1 Data for VIP236 and Updates on Pipeline Progress at the American Association for Cancer Research (AACR) Annual Meeting 2024April 2, 2024 | investorplace.comVINC Stock Earnings: Vincerx Pharma Beats EPS for Q4 2023April 1, 2024 | finanznachrichten.deVincerx Pharma, Inc.: Vincerx Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate UpdateApril 1, 2024 | finance.yahoo.comVincerx to Host Virtual Investor Event Reviewing Preliminary Phase 1 VIP236 Data Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024March 29, 2024 | finance.yahoo.comVincerx Pharma Inc (VINC) Reports Q4 and Full Year 2023 Financials: A Close LookMarch 29, 2024 | marketwatch.comVincerx Pharma Cuts Funding-Sufficiency View to 3Q From Late 2024March 29, 2024 | globenewswire.comVincerx Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate UpdateMarch 19, 2024 | edition.cnn.comVincerx Pharma IncMarch 12, 2024 | benzinga.comWhy Asana Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day SessionMarch 7, 2024 | markets.businessinsider.comBuy Rating Affirmed for Vincerx Pharma Ahead of AACR Presentation: Promising Developments in Oncology Drug PipelineSee More Headlines Receive VINC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vincerx Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/14/2024Today5/20/2024Next Earnings (Estimated)8/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:VINC CUSIPN/A CIK1796129 Webvincerapharma.com Phone650-800-6676FaxN/AEmployees42Year FoundedN/APrice Target and Rating Average Stock Price Target$5.00 High Stock Price Target$5.00 Low Stock Price Target$5.00 Potential Upside/Downside+624.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($1.79) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-40,160,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-261.83% Return on Assets-145.47% Debt Debt-to-Equity RatioN/A Current Ratio0.72 Quick Ratio2.63 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.03) per share Price / Book-23.02Miscellaneous Outstanding Shares21,410,000Free Float16,509,000Market Cap$14.79 million OptionableNot Optionable Beta1.53 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesDr. Ahmed M. Hamdy M.D. (Age 59)Co-Founder, Chairman & CEO Comp: $657.54kDr. Raquel E. Izumi Ph.D. (Age 54)Co-Founder, President, COO, Secretary & Director Comp: $591.54kMr. Alexander A. Seelenberger M.B.A. (Age 45)Chief Financial Officer Comp: $491.69kMr. Tom C. Thomas J.D. (Age 64)Founder, General Counsel & Chief Legal Officer Comp: $444.14kDr. John C. Byrd M.D.Founder & Chairman of Scientific Advisory BoardDr. Hans-Georg Lerchen Ph.D.Chief Scientific OfficerMs. Gabriela JairalaSr Executive Director of Investor Relations & Corporate CommunicationsMs. Karen QuarfordVice President of Quality Operations & ComplianceMs. Melissa Merrick SPHRSenior Director of People & Culture and Head of Human ResourceDr. Beatrix Stelte-Ludwig Ph.D.Executive Chief Development OfficerMore ExecutivesKey CompetitorsFlora GrowthNASDAQ:FLGCTraws PharmaNASDAQ:TRAWTalpheraNASDAQ:TLPHMinerva NeurosciencesNASDAQ:NERVNeuroSense TherapeuticsNASDAQ:NRSNView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 153,575 shares on 5/10/2024Ownership: 3.115%Acadian Asset Management LLCSold 36,571 shares on 5/10/2024Ownership: 0.025%Alexander A SeelenbergerBought 10,500 shares on 8/11/2023Total: $9,975.00 ($0.95/share)Ahmed Md HamdyBought 16,900 shares on 8/9/2023Total: $16,055.00 ($0.95/share)View All Insider TransactionsView All Institutional Transactions VINC Stock Analysis - Frequently Asked Questions Should I buy or sell Vincerx Pharma stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vincerx Pharma in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" VINC shares. View VINC analyst ratings or view top-rated stocks. What is Vincerx Pharma's stock price target for 2024? 1 brokerages have issued 1 year price targets for Vincerx Pharma's shares. Their VINC share price targets range from $5.00 to $5.00. On average, they anticipate the company's stock price to reach $5.00 in the next year. This suggests a possible upside of 624.0% from the stock's current price. View analysts price targets for VINC or view top-rated stocks among Wall Street analysts. How have VINC shares performed in 2024? Vincerx Pharma's stock was trading at $1.18 at the beginning of 2024. Since then, VINC shares have decreased by 41.5% and is now trading at $0.6906. View the best growth stocks for 2024 here. When is Vincerx Pharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 5th 2024. View our VINC earnings forecast. How were Vincerx Pharma's earnings last quarter? Vincerx Pharma, Inc. (NASDAQ:VINC) issued its earnings results on Tuesday, May, 14th. The company reported ($0.34) EPS for the quarter, missing analysts' consensus estimates of ($0.26) by $0.08. Who are Vincerx Pharma's major shareholders? Vincerx Pharma's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (3.12%) and Acadian Asset Management LLC (0.02%). Insiders that own company stock include Ahmed Md Hamdy, Alexander A Seelenberger, Andrew I Mcdonald, Christopher P Lowe, Laura I Bushnell, Raquel E Izumi and Tom C Thomas. View institutional ownership trends. How do I buy shares of Vincerx Pharma? Shares of VINC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:VINC) was last updated on 5/20/2024 by MarketBeat.com Staff From Our PartnersRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersDoes this make you sick?Allegiance GoldThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarUrgent Nvidia WarningAltimetryShocking: One AI startup's revenue could surge 4,735%Manward PressBill Gates is all about this tiny $2 stockTimothy Sykes Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vincerx Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
